Publications

Abivax’s lead drug candidate, obefazimod (originally known as ABX464), is an investigational drug candidate that has not yet been approved for commercial use in any jurisdiction, but it has already garnered plenty of attention in the industry. The following collection of publications can offer a more complete understanding of the potential of obefazimod.

2025

Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study

Severine Vermeire, Josianne Nitcheu, Paul Gineste, Aurélien Flatres, Julien Santo, Didier Scherrer, Laurent Peyrin-Biroulet, Parambir S Dulai, Silvio Danese, Marla Dubinsky, Herbert Tilg, Britta Siegmund, Tadakazu Hisamatsu, Kejia Shan, Christopher J Rabbat, Bruce E Sands

J Crohns Colitis.2025;19(5):jjaf074.

2023

Impact of obefazimod on viral persistence, inflammation, and immune activation in people with human immunodeficiency virus on suppressive antiretroviral therapy

Silvia Bernal, Maria C Puertas, Sara Morón-López, Ross D Cranston, Víctor Urrea, Judith Dalmau, María Salgado, Cristina Gálvez, Itziar Erkizia, Ian McGowan, Didier Scherrer, Boris Revollo, Guillem Sirera, José Ramón Santos, Bonaventura Clotet, Roger Paredes, Javier Martinez-Picado

J Infect Dis.2023;228(9):1280-1291.
Obefazimod: a first-in-class drug for the treatment of ulcerative colitis

Séverine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich, Didier Scherrer, Paul Gineste, Laurence d’Agay, Bruce E Sands

J Crohns Colitis.2023;17(10):1689-1697.
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Pedro Giavina-Bianchi, Eric Cua, Karine Risso, Véronique Mondain, Anaïs Vissian, Cécile Joie, Philippe Pouletty, Paul Gineste, Hartmut J Ehrlich, Jorge Kalil

J Allergy Clin Immunol Glob.2023;2(4):100140.
ABX464 (obefazimod) upregulates miR124 to reduce proinflammatory markers in inflammatory bowel diseases

Cécile Apolit, Noëlie Campos, Audrey Vautrin, Christina Begon-Pescia, Laure Lapasset, Didier Scherrer, Paul Gineste, Hartmut Ehrlich, Aude Garcel, Julien Santo, Jamal Tazi

Clin Transl Gastroenterol.2023;14(4):e00560.

2022

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Severine Vermeire, Bruce E Sands, Herbert Tilg, Zsolt Tulassay, Radoslaw Kempinski, Silvio Danese, Ivan Bunganič, Josianne Nitcheu, Julien Santo, Didier Scherrer, Sophie Biguenet, Hartmut J Ehrlich, Jean-Marc Steens, Paul Gineste, William J Sandborn

Lancet Gastroenterol Hepatol.2022;7(11):1024-1035.
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez

Ann Rheum Dis.2022;81(8):1076-1084.

2021

Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial

Séverine Vermeire, Xavier Hébuterne, Herbert Tilg, Gert De Hertogh, Paul Gineste, Jean-Marc Steens; ABX464 Investigators

Gastroenterology.2021;160(7):2595-2598.e3.
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases

Jamal Tazi, Christina Begon-Pescia, Noëlie Campos, Cécile Apolit, Aude Garcel, Didier Scherrer

Drug Discov Today.2021;26(4):1030-1039.

2019

Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

Audrey Vautrin, Laurent Manchon, Aude Garcel, Noëlie Campos, Laure Lapasset, Abdelhamid Mahdi Laaref, Roman Bruno, Marie Gislard, Emeric Dubois, Didier Scherrer, Hartmut J Ehrlich, Jamal Tazi

Sci Rep.2019;9(1):792.

2017

The anti-Hiv candidate Abx464 dampens intestinal inflammation by triggering Il-22 production in activated macrophages

Karim Chebli, Laura Papon, Conception Paul, Aude Garcel, Noëlie Campos, Didier Scherrer, Hartmut J Ehrlich, Michael Hahne, Jamal Tazi

Sci Rep.2017;7(1):4860.
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

Didier Scherrer, Regine Rouzier, P Noel Barrett, Jean-Marc Steens, Paul Gineste, Robert L Murphy, Jamal Tazi, Hartmut J Ehrlich

J Antimicrob Chemother.2017;72(3):820-828.

2016

Randomized trial of food effect on pharmacokinetic parameters of ABX464 administered orally to healthy male subjects

Didier Scherrer, Regine Rouzier, Marine Cardona, P Noel Barrett, Jean-Marc Steens, Paul Gineste, Robert L Murphy, Jamal Tazi, Hartmut J Ehrlich

Antimicrob Agents Chemother.2016;61(1):e012288-16.

2015

Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis

Noëlie Campos, Renier Myburgh, Aude Garcel, Audrey Vautrin, Laure Lapasset, Erika Schläpfer Nadal, Florence Mahuteau-Betzer, Romain Najman, Pauline Fornarelli, Katjana Tantale, Eugénia Basyuk, Martial Séveno, Julian P Venables, Bernard Pau, Edouard Bertrand, Mark A Wainberg, Roberto F Speck, Didier Scherrer, Jamal Tazi

Retrovirology.2015;12:30.